1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68F6FC78F457862BE00258D070038A48A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-impact-equation-linking-activities-strategic-outcomes-real-world
18
19
20216.73.216.147
21
22
23globalbenchmarking.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Medical Affairs Excellence

The Medical Affairs Impact Equation: Linking Activities with Strategic Outcomes to Drive Real-World Impact

ID: POP-412


Features:

19 Info Graphics

23 Data Graphics

430+ Metrics

21 Narratives


Pages: 51


Published: 2025


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
This report equips Medical Affairs executives with actionable benchmarks and strategic insights to enable them to connect day-to-day activities with critical external outcomes among KOLs, HCPs, patients and other stakeholders. By linking leading indicators—such as MSL insights, evidence generation, and stakeholder engagement—to lagging indicators like guideline evolution, patient adoption, and care change, leaders can strengthen measurement frameworks, refine alignment, and elevate Medical’s impact across the product lifecycle.

In a landscape where traditional metrics fall short, Medical leaders are under mounting pressure to prove how Medical Affairs creates tangible value for patients, providers, and the business—moving beyond activity counts to measurable, outcome-driven influence.

Developed by Best Practices, LLC, this research reveals how top organizations are advancing the Medical Affairs impact equation through strategic indicator mapping, real-world data integration, and innovative measurement approaches. At the same time, it highlights a persistent capability gap: the inability to consistently tie activities to outcomes. For all Medical leaders, closing this gap is not only urgent but transformative—an opportunity to redefine Medical’s value narrative and firmly position it as a driver of real-world impact.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Biopharmaceutical; Manufacturing; Consumer Products; Diagnostic; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Alcon; Alnylam Pharmaceuticals; Amgen; Astellas Pharma; Azurity Pharmaceuticals; Bayer; Boehringer Ingelheim; CSL Vifor; EMD Serono; Eton Pharmaceuticals; Eurofarma; Gilead Sciences; Grifols; Jazz Pharmaceuticals; Johnson & Johnson; Merck & Co.; Novartis; Organon; Orphalan; Otsuka; Pacira BioSciences; QIAGEN; Sanofi; Santen Pharmaceutical; Scholar Rock; Stallergenes Greer; Supernus; Syndax Pharmaceuticals; Takeda

Study Snapshot

Best Practices, LLC engaged 40 Medical Affairs executives from 30 biopharma companies. The research team also conducted deep-dive interviews with select participants to capture additional insights on how Medical teams are linking activities to strategic outcomes and measuring impact.

Key topics covered in this report include:

  • Medical Affairs Leading and Lagging Indicators
  • Strategic Impact Measurement Frameworks
  • Real-World Data Sources and Linkability
  • Medical Insights and Launch Success
  • Performance Measurement and KPIs

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Linking Activities to Outcomes Is the New Standard: 62% of Medical Affairs organizations link some activities directly to strategic external outcomes. However, only 5% have achieved full linkage—highlighting a major opportunity for improvement.
  • Real-World Data Is Key to Demonstrating Impact: Organizations are increasingly using claims, EHR, and CRM data to trace Medical’s influence on outcomes like diagnosis rates, treatment adoption, and care model changes.
Table of Contents

Sr. No.
Topic
Slide No.
I. Executive SummaryPg. 5
II. Leading Indicators Which Demonstrate ValuePg. 15
III. Linking Leading & Lagging IndicatorsPg. 21
IV. Lagging Indicators of Medical ImpactPg. 29
V. Assessing Metrics, Outcomes & Data Sources for High ImpactPg. 41
VI. Respondent DemographicsPg. 48
VII. About Best Practices, LLCPg. 51

    List of Charts & Exhibits

    I. Executive Summary

    • One-page executive summary
    • Participating benchmark companies
    • Executive takeaways from the study
    • Medical impact cycle: Connecting activities to strategic outcomes
    • Key quantitative study findings
    • Insights vs. impact pathway

    II. Leading Indicators Which Demonstrate Value

    • Top-rated activity metrics across Medical Affairs
    • Case study: Measuring MSL strategic impact across three workstreams
    • Top field activity metrics
    • Top non-field activity metrics
    • Cycle of impact: Real-world examples showing the impact of disease awareness and knowledge retention

    III. Linking Leading & Lagging Indicators

    • Benchmark activities to outcomes linkage rates across organizations
    • Most linkable medical activities to key external outcomes
    • Linking a successful outcome to many activities
    • Most linkable field activities to critical external outcomes
    • Cycle of impact: Real-world examples showing the impact of medical insights
    • Most linkable non-field activities to critical external outcomes
    • Cycle of impact: Real-world examples showing the impact of Congress presentations and post-Congress tracking

    IV. Lagging Indicators of Medical Impact

    • Case study: Driving strategic outcomes through AI-identified care gaps and targeted MSL engagement
    • Prioritizing strategic outcomes and evaluating linkability to medical activities
    • Measuring the gap between outcome importance and linkability
    • Linkability trends across lagging indicators
    • Linking real-world data outcomes to medical activities
    • Connecting provider-level outcomes to tactical medical engagement
    • Measuring Medical’s influence on launch strategy, guidelines, and access
    • Cycle of impact: Real-world examples showing the impact of patient support
    • Cycle of impact: Real-world examples showing the impact of disease awareness and knowledge retention Through field and digital engagement
    • Mapping perceived vs. measured impact across lagging indicators
    • Key challenges in linking medical tactics to strategic outcomes

    V. Assessing Metrics, Outcomes & Data Sources for High Impact

    • Differentiating activity metrics between new and mature products
    • Tailoring strategic outcome measurement to product lifecycle stage
    • Revisiting metrics over time to align activities with strategic goals
    • Navigating competing strategic objectives across medical levels
    • Critical data sources to trace medical impact
    • Tracking data granularity to strengthen activity-to-outcome linkage

    VI. Respondent Demographics

    • Therapeutic areas represented in the study
    • Geographic coverage of benchmarked Medical Affairs roles